Actor-Network Theory: a tool to support ethical analysis of commercial genetic testing

被引:44
作者
Williams-Jones, B [1 ]
Graham, JE [1 ]
机构
[1] Univ Cambridge, Fac Social Polit Sci, Ctr Family Res, Cambridge CB2 3RF, England
基金
美国国家卫生研究院;
关键词
D O I
10.1080/1463677032000147225
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Social, ethical and policy analysis of the issues arising from gene patenting and commercial genetic testing is enhanced by the application of science and technology studies, and Actor-Network Theory ( ANT) in particular. We suggest the potential for transferring ANT's flexible nature to an applied heuristic methodology for gathering empirical information and for analysing the complex networks involved in the development of genetic technologies. Three concepts are explored in this paper-actor-networks, translation, and drift - and applied to the case of Myriad Genetics and their commercial BRACAnalysis genetic susceptibility test for hereditary breast cancer. Treating this test as an active participant in socio-technical networks clarifies the extent to which it interacts with, shapes and is shaped by people, other technologies, and institutions. Such an understanding enables more sophisticated and nuanced technology assessment, academic analysis, as well as public debate about the social, ethical and policy implications of the commercialization of new genetic technologies.
引用
收藏
页码:271 / 296
页数:26
相关论文
共 117 条
[1]  
Akrich M., 1992, Shaping Technology/Building Society: Studies in Sociotechnical Change
[2]  
[Anonymous], [No title captured]
[3]   Identification of genetic susceptibility to common diseases - the case for regulation [J].
Baird, PA .
PERSPECTIVES IN BIOLOGY AND MEDICINE, 2002, 45 (04) :516-528
[4]  
BAIRD PA, 2001, ISUMA CANADIAN J POL, V2, P94
[5]   French challenge to BRCA1 patent underlies European discontent [J].
Benowitz, S .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (02) :80-81
[6]   Myriad's rationale for wider testing [J].
Birmingham, K .
NATURE MEDICINE, 1997, 3 (07) :709-709
[7]  
Burgess MM, 1996, AM J MED GENET, V62, P6, DOI 10.1002/(SICI)1096-8628(19960301)62:1<6::AID-AJMG2>3.0.CO
[8]  
2-X
[9]   Beyond consent: ethical and social issues in genetic testing [J].
Burgess, MM .
NATURE REVIEWS GENETICS, 2001, 2 (02) :147-151
[10]  
BURGESS MM, 1999, COMMERCIALIZATION GE, P181